Früher|Nächster

Forschungsfortschritte bei Tiermodellen der chronisch obstruktiven Lungenerkrankung und der Intervention mit chinesischer Medizin

  • role： First author第一作者
  • Affiliation：

    Liaoning University of Traditional Chinese Medicine（TCM）， Shenyang 110847，China

  • Email：2097893477@qq.com
  • Introduction：邹吉宇，在读博士，从事中医药治疗肺系疾病的基础和临床研究，E-mail：2097893477@qq.com
ZOU Jiyu1,  
  • Affiliation：

    The Affiliated Hospital of Liaoning University of TCM， Shenyang 110000，China

PANG Lijian2,  
  • Affiliation：

    The Affiliated Hospital of Liaoning University of TCM， Shenyang 110000，China

WANG Tianjiao2,  
  • Affiliation：

    The Affiliated Hospital of Liaoning University of TCM， Shenyang 110000，China

ZANG Ningzi2,  
  • Affiliation：

    The Affiliated Hospital of Liaoning University of TCM， Shenyang 110000，China

ZHAO Zhongxue2,  
  • Affiliation：

    The Affiliated Hospital of Liaoning University of TCM， Shenyang 110000，China

LIU Yongming2,  
  • Affiliation：

    Liaoning University of Traditional Chinese Medicine（TCM）， Shenyang 110847，China

SI Qi1,  
  • Affiliation：

    Liaoning University of Traditional Chinese Medicine（TCM）， Shenyang 110847，China

CAO Tianya1,  
  • Affiliation：

    Liaoning University of Traditional Chinese Medicine（TCM）， Shenyang 110847，China

MA Xuenan1,  
  • Affiliation：

    Liaoning University of Traditional Chinese Medicine（TCM）， Shenyang 110847，China

WANG Ying1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Liaoning University of Traditional Chinese Medicine（TCM）， Shenyang 110847，China

  • Email：1548739538@qq.com
  • Introduction：王佳然，博士，从事中医肺系疾病基础和临床研究，E-mail：1548739538@qq.com； *
WANG Jiaran1*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Liaoning University of Traditional Chinese Medicine（TCM）， Shenyang 110847，China

  • Email：deanoftcm@126.com
  • Introduction：吕晓东，博士，主任医师，教授，博士生导师，从事中医肺系疾病基础和临床研究，E-mail：deanoftcm@126.com
LYU Xiaodong1*

Resümee

Chronisch obstruktive Lungenerkrankung (COPD) ist eine der drei weltweit führenden Todesursachen. Es handelt sich um eine komplexe systemische Erkrankung mit hoher Prävalenz, hoher Mortalität, hoher Behinderungsrate, häufigen akuten Exazerbationen und verschiedenen extrapulmonalen Komorbiditäten. Die Pathogenese ist komplex, und die westliche Medizin verfügt derzeit über keine wirksame spezifische Therapie zur vollständigen Heilung. Traditionelle chinesische Medizin zeichnet sich durch multikomponentige und mehrzielige Eigenschaften aus, die bei der Behandlung von COPD Vorteile durch mehrfaches Eingreifen in verschiedene Phasen, Wege und Mechanismen bieten. Daher ist die Anwendung chinesischer medizinischer Prinzipien zur Erforschung der COPD-Pathogenese und zur Entdeckung wirksamer Behandlungsmedikamente ein Kernpunkt der modernen Forschung. Tiermodelle sind ein wichtiger Bestandteil der medizinischen Forschung; die Wahl geeigneter Tiere, die Anwendung vernünftiger Modellierungsverfahren zur Nachbildung stabiler Tiermodelle, die klinische Manifestation und physiopathologische Merkmale von COPD exakt abbilden, sowie die Anwendung geeigneter Bewertungstechniken zur Feststellung des Erfolgs der Modelle sind grundlegende Aufgaben experimenteller Studien. Die Beobachtung der Intervention chinesischer Arzneimittel an COPD-Tiermodellen, die Erkundung spezifischer Wirkwege und Regulationsmechanismen sowie die Entdeckung wirksamer Einzelbestandteile, Einzelkräuter und chinesischer Rezepturen bilden das Herzstück experimenteller Forschung. Aktuelle Untersuchungen zu COPD-Tiermodellen umfassen hauptsächlich den Modellaufbau, die Modellbewertung, Wirksamkeitsbeobachtung und Mechanismenforschung. In den letzten Jahren gab es keine systematische Zusammenfassung, Aktualisierung und Reflexion der Forschung zur chinesischen Medizin in COPD-Tiermodellen. Diese Studie gibt einen Überblick über die Auswahl der Modelltiere, die Herstellung von COPD-Tiermodellen, Bewertungsmethoden sowie die Intervention chinesischer Arzneimittel in diesen Modellen, fasst den Forschungsstand zusammen, identifiziert bestehende Probleme und strebt Verbesserungen an, um wissenschaftliche Forschung und klinische Behandlung von COPD zu unterstützen.

Schlüsselwort

chronisch obstruktive Lungenerkrankung (COPD);Tiermodell;chinesische Medizin;Kombination von Krankheit und Syndrom;Modellevaluation

References

  1. 1.
    Global burden of 369 diseases and injuries in 204 countries and territories，1990-2019：A systematic analysis for the global burden of disease study 2019［J］.Lancet，2020，396（10258）：1204-1222.
  2. 2.
    LI J S.International clinical practice guideline of Chinese medicine chronic obstructive pulmonary disease［J］.World J Tradit Chin Med，2020，15（7）：1084-1092.
  3. 3.
    KAHNERT K，JÖRRES R A，BEHR J，et al.The diagnosis and treatment of COPD and its comorbidities［J］.Dtsch Arztebl Int，2023，120（25）：434-444.
  4. 4.
    LIANG K K，WANG Z W，HUANG K T，et al.New progress in the study of PI3K-Akt signaling pathway regulating airway inflammatory response in chronic obstructive pulmonary disease［J］.Chin J Respir Crit Care Med，2022，21（10）：751-755.
  5. 5.
    GUO W X，CHEN S N，LI B，et al.Research progress on oxidative stress mechanism and TCM treatment in chronic obstructive pulmonary disease［J］.Shanxi J Tradit Chin Med，2022，38（3）：68-70.
  6. 6.
    PENG X，LIU J，LUAN Z Y，et al.Pathogenesis of airway mucus hypersecretion in chronic obstructive pulmonary disease and intervention of traditional Chinese medicine：A review［J］.Chin J Exp Tradit Med Form，2024，30（4）：228-239.
  7. 7.
    LU J，HU X L，ZHENG X T，et al.Research progress of traditional Chinese medicine intervention on immune imbalance in chronic obstructive pulmonary disease［J］.Shanxi J Tradit Chin Med，2022，38（12）：59-61.
  8. 8.
    ZHU Y Y，TIAN M，FANG C B，et al.Chronic obstructive pulmonary disease and cell senescence［J］.Henan J Tradit Chin Med，2023，43（11）：1645-1648.
  9. 9.
    Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society，Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physicians. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease（revised version 2021）［J］.Chin J Tuberc Respir Dis，2021，44（3）：170-205.
  10. 10.
    AGUSTI A，FABBRI L M，SINGH D，et al.Inhaled corticosteroids in COPD：Friend or foe？［J］.Eur Respir J，2018，52（6）：1801219.
  11. 11.
    Internal Medicine Committee of World Federation of Chinese Medicine Societies. Guideline of integrated Chinese and western medicine for diagnosis and treatment of chronic obstructive pulmonary disease［J］.Chin J Evid Base Med，2023，23（10）：1117-1128.
  12. 12.
    ZANG N Z，LI P，PANG L J，et al.Review of research progress in animal model of lung disease related syndromes［J］.Tradit Chin Med Materia Med-World Sci Technol，2024，26（3）：721-730.
  13. 13.
    LI Y Y，GAO B Z.Development status，problems and countermeasures of animal models of traditional Chinese medicine［J］.Chin J Tradit Chin Med Pharm，2024，39（1）：49-53.
  14. 14.
    LU M X，XUE H，ZHANG B H，et al.A review and comment of animal models of spleen deficiency syndrome［J］.Tradit Chin Med Materia Med-World Sci Technol，2024，26（3）：652-658.
  15. 15.
    ZHOU L R，CUI X L.Development of ananimal model for chronic obstructive pulmonary-related disease［J］.Chin J Lab Anim Sci，2022，30（8）：1121-1127.
  16. 16.
    RYDEL-TORMANEN K，JOHNSON J R.The applicability of mouse models to the study of human disease［J］.Methods Mol Biol，2019，1940：3-22.
  17. 17.
    WEMYSS-HOLDEN S A，PORTER K J，BAXTER P，et al.The laryngeal mask airway in experimental pig anaesthesia［J］.Lab Anim，1999，33（1）：30-34.
  18. 18.
    TANNER L，SINGLE A B.Animal models reflecting chronic obstructive pulmonary disease and related respiratory disorders：Translating pre-clinical data into clinical relevance［J］.J Innate Immun，2020，12（3）：203-225.
  19. 19.
    PARK S S，KIKKAWA Y，GOLDRING I P，et al.An animal model of cigarette smoking in beagle dogs：Correlative evaluation of effects on pulmonary function，defense，and morphology［J］.Am Rev Respir Dis，1977，115（6）：971-979.
  20. 20.
    ZWICKER G M，FILIPY R E，PARK J F，et al.Clinical and pathological effects of cigarette smoke exposure in beagle dogs［J］.Arch Pathol Lab Med，1978，102（12）：623-628.
  21. 21.
    RAJU S V，KIM H，BYZEK S A，et al.A ferret model of COPD-related chronic bronchitis［J］.JCI Insight，2016，1（15）：e87536.
  22. 22.
    PLOPPER G G，HYDE D M.The non-human primate as a model for studying COPD and asthma［J］.Pulm Pharmacol Ther，2008，21（5）：755-766.
  23. 23.
    LI J，ZHANG L Y，YONG W X，et al.Progress in the evaluation for chronic obstructive pulmonary disease using a rodent model［J］.Chin J Lab Anim Sci，2022，30（5）：692-697.
  24. 24.
    LIAO J S，ZHE Z，LI F S，et al.Effects of compound Fo'ercao mixture on TLR4/MyD88/NF-κB signaling pathway in a rat model of chronic obstructive pulmonary disease［J］.Chin Tradit Pat Med，2024，46（3）：810-816.
  25. 25.
    CHEN Q Y，LIU M H，WEI C C，et al.Inhaled smoke combined with nasal drip of Streptococcus pneumoniae to build a COPD rat model［J］.Basic Med Sci Clin，2020，40（10）：1407-1408.
  26. 26.
    SHEN T T，LI S Y，LI Y，et al.Role of lRS-1/PI3K signaling axis in the effects of Bufei Jianpi formula on mitochondrial damage in skeletal muscle of chronic obstructive pulmonary disease rats［J］.Chin J Comp Med，2024，34（3）：57-67.
  27. 27.
    QIN Y Q，DONG H R，YANG J F，et al.The evaluation of effective-component compatibility of Bufei Yishen formula Ⅲ and component compatibility in treating airway remodeling of COPD［J］.Chin Gen Pract，2024，27（33）：4196-4203.
  28. 28.
    ITO J T，DE BRITO CERVILHA D A，LOURENÇO J D，et al.Th17/Treg imbalance in COPD progression：A temporal analysis using a cs-induced model［J］.PLoS One，2019，14（1）：e0209351.
  29. 29.
    CARAMORI G，KIRKHAM P，BARCZYK A，et al.Molecular pathogenesis of cigarette smoking-induced stable COPD［J］.Ann N Y Acad Sci，2015，1340：55-64.
  30. 30.
    LI Z G，WANG C B，PENG B，et al.Establishment of rat model of chronic obstructive pulmonary disease with stagnated phlegm obstructing the lung［J］.Tianjin J Tradit Chin Med，2010，27（1）：43-45.
  31. 31.
    WANG C B，FANG L，WANG J Q，et al.Influence of Qibai Pingfei capsule on expression of HIF-1α and PDGF in serum of COPD rats with syndrome of phlegm and blood stasis obstructing lung［J］.Chin J Tradit Chin Med Pharm，2015，30（9）：3270-3272.
  32. 32.
    ZHANG Z，YANG Y R，LIU Y，et al.Effects of Guizhi Fuling pill on airway remodeling in mouse models of COPD［J］.Chin Tradit Pat Med，2023，45（11）：3592-3598.
  33. 33.
    LI J，SU J，DONG Y J，et al.Effect of Polygonati Rhizoma aqueous extract on chronic obstructive pulmonary disease in rats［J］.China J Chin Mater Med，2024，49（16）：4321-4328.
  34. 34.
    DING H Z，WU D，YANG Q J，et al.Establishment and evaluation of rat model for chronic obstructive pulmonary disease with lung-spleen Qi deficiency［J］.Chin J Exp Tradit Med Form，2023，29（23）：47-55.
  35. 35.
    SHI Y L，WANG Y C，YANG Z，et al.Effect of Xuanfei Zhisou prescription on IL-17 signaling pathway in COPD model rats［J］.Chin J Exp Tradit Med Form，2024，30（9）：28-39.
  36. 36.
    XIE R F，HUANG C Y，LI M M，et al.Effects of Buyuan decoction on airway remodeling in COPD rats by regulating NLRP3 inflammasome signaling pathway［J］.Chin J Tradit Chin Med Pharm，2023，38（11）：5459-5463.
  37. 37.
    YANG Y，DI T T，ZHANG Z X，et al.Dynamic evolution of emphysema and airway remodeling in two mouse models of COPD［J］.BMC Pulm Med，2021，21（1）：134-144.
  38. 38.
    YIN H J，HUANG Y.Research progress on animal model of disease syndrome combination［J］.Chin J Integr Tradit Clin West Med，2013，33（1）：8-10．
  39. 39.
    LI R X，CHEN S N，LI Z H，et al.Effect of Lijinfang on the differentiation of CD4+ T cells into Th17 cells in COPD rats with lung Qi deficiency syndrome［J］.Lishizhen Med Mater Med Res，2021，32（5）：1032-1034.
  40. 40.
    CI H M，XU H R，DING H Z，et al.Study on the mechanism of Shenqi Wenfei decoction in the treatment of COPD with lung Qi deficiency syndrome based on Th17 / Treg imbalance［J］.Lishizhen Med Mater Med Res，2024，35（1）：65-67.
  41. 41.
    SHEN J X，ZHU X，CHEN Y Z，et al.Effect of Bufei decoction on lung-gut axis in rats with lung Qi-deficiency syndrome of chronic obstructive pulmonary disease［J］.Chin J Exp Tradit Med Form，2023，29（7）：47-56.
  42. 42.
    TIAN J，YE Z Y，FU D D，et al.Effect of Shengyang Yiwei decoction on histopathology，serum inflammatory factors and peripheral blood Th17/Treg balance in chronic obstructive pulmonary disease model rats with lung-spleen qi deficiency syndrome［J］.J Tradit Chin Med，2023，64（1）：62-70.
  43. 43.
    HU X Z，HONG B，CHEN X E.Analysis of characteristics of intestinal flora in rat models with chronic obstructive pulmonary disease of lung and spleen deficiency based on 16S rRNA sequencing［J］.Chin J Nosocomiololy，2023，33（14）：2086-2090.
  44. 44.
    TAN G B，BAI Z P，LIU F，et al.Establishment of rat model with chronic obstructive pulmonary disease of Yin-deficiency and phlegm-retention syndrome type［J］.Guide J Tradit Chin Med Pharm，2015，21（22）：4-8.
  45. 45.
    LU S Y，SUN G R.Dynamic study of AQP1，MUC5ac of lung tissue of chronic obstructive pulmonary disease model rats with syndrome of accumulation of cold fluid in the lung［J］.Shandong J Tradit Chin Med，2014，33（2）：127-130.
  46. 46.
    ZHU Z Q，SHI M Y，FANG L，et al.Effect of Qibai Pingfei capsule on pulmonary inflammation and pulmonary function in rats with chronic obstructive pulmonary disease with syndrome of phlegm and blood stasis obstructing the lung［J］.J Anhui Univ Chin Med，2021，40（6）：52-57.
  47. 47.
    LI Y L，LI Y，MA J L，et al.Effects of Sijunzi decoction combined with Sanzi Yangqin decoction on lung function and lung tissue injury in mice with COPD［J］.Liaoning J Tradit Chin Med，2024，51（5）：193-196，225.
  48. 48.
    GUO M，LI T，YANG X X，et al.Recombinant human CC16 protein improves lung function in chronic obstructive pulmonary disease mice and its mechanism［J］.Chin J Pathophysiol，2023，39（10）：1789-1795.
  49. 49.
    LIU S，TIAN L，HU Q S，et al.Explore the intervention effect of acupuncture at Zusanli on rats with chronic obstructive pulmonary disease based on TLR4/MyD88 pathway［J］.Chin J Gerontol，2024，44（10）：2507-2511.
  50. 50.
    TIAN Y G，LIU X F，CHEN L，et al.Research progress of lung histopathological evaluation methods in animal models of chronic obstructive pulmonary disease［J］.Chin J Gerontol，2023，43（6）：1495-1498.
  51. 51.
    LIU S J，LI Y，FAN Z Y，et al.Pomalidomide improves airway inflammation and mucus hypersecretion in COPD rats by inhibiting TNF-α/NF-κB signaling pathway［J］.Med J Chin PLA，2024，49（1）：91-98.
  52. 52.
    ZHOU Z X，WANG S，TANG Z，et al.Effect of icariin on improving efferocytosis and phagocytosis dysfunction of alveolar macrophages in chronic obstructive pulmonary disease model mice based on Rac1 signaling pathway［J］.Chin Tradit Herb Drugs，2024，55（1）：159-170.
  53. 53.
    SASAKI M，CHUBACHI S，KAMEYAMA N，et al.Evaluation of cigarette smoke-induced emphysema in mice using quantitative micro-computed tomography［J］.Am J Physiol Lung Cell Mol Physiol，2015，308（10）：L1039-L1045.
  54. 54.
    ZHANG D.Ouantitative study of COPD about emphysema and airway remodeling by lmaging［D］.Shanghai：Naval Medical University，2018.
  55. 55.
    BAO H L，TE R G L，QI M G.Improvement effects of safflower yellow on lung function of chronic obstructive pulmonary disease model rats［J］.J China Pharm，2021，32（13）：1578-1582.
  56. 56.
    YAO M X，WANG C Y，XIE J H，et al.Effects of aqueous extracts from Ficus pumila on pulmonary dysfunction and inflammation in rats with chronic obstructive pulmonary disease［J］.Food Mach，2023，39（3）：147-152.
  57. 57.
    THIBOUTOT J，YUAN W，PARK H C，et al.Current advances in COPD imaging ［J］.Acad Radiol，2019，26（3）：335-343.
  58. 58.
    YANG S，LI L L，WEN P，et al.Study on intervention effect of ginger on chronic obstructive pulmonary disease rats with cold fluid in the lung syndrome［J］.World J Tradit Chin Med，2018，13（4）：803-807.
  59. 59.
    ZHOU F C，YANG Q J，WU D，et al.Shenqi Tiaoshen formula inhibits COPD mediated bone resorption through OPG/RANKL/NF-κB/MMP-9 pathway［J］.Pharmacol Clin Chin Mater Med，2024，40（4）：54-60.
  60. 60.
    ZHENG L，LUO Z Y，XIAO M，et al.Yougui pill reduces airway inflammation in COPD rats with syndrome of kidney-Yang deficiency by inhibiting Leptin/JAK2/STAT3 signaling pathway［J］.Chin J Exp Tradit Med Form，2024，30（14）：17-26.
  61. 61.
    CHEN P，CHEN X J，DU Z M，et al.Mechanism of peimine improving chronic obstructive pulmonary disease induced by lipopolysaccharide combined with cigarette smoke in mice［J］.Acta Anat Sin，2024，55（2）：215-221.
  62. 62.
    LI Y，WU Z R，HAO S Y，et al.Experimental study on reducing oxidative stress of mice with chronic obstructive pulmonary disease by Jianpi Bushen Yifei decoction［J］.J Emerg Syndrome Tradit Chin Med，2023，32（12）：2090-2093，2111.
  63. 63.
    SP N，KANG D Y，LEE J M，et al.Mechanistic insights of anti-immune evasion by nobiletin through regulating miR-197/STAT3/PD-L1 signaling in non-small cell lung cancer（NSCLC）cells［J］.Int J Mol Sci，2021，22（18）：9843.
  64. 64.
    CHEN J L，LI Q，ZHOU X D，et al.Inhibitory effect of nobiletin on airway mucus hypersecretion in model rats with chronic obstructive pulmonary disease and its molecular mechanism［J］.J Jilin Univ：Med Ed，2024，50（2）：295-302.
  65. 65.
    LI G F，LIU S J，LI Y，et al.Beneficial effects of Tiao-Bu Fei-Shen therapies on airway mucus hypersecretion in chronic obstructive pulmonary disease rats via inhibition of ERK1/2 signaling pathway［J］.Chin J Lab Anim Sci，2024，32（4）：411-422.
  66. 66.
    WU Y Y，OUYANG G L，CHEN X H，et al.Effects of Guben Pingchuan formula on MUC5AC level in the airway of chronic obstructive pulmonary disease model rats［J］.J Hunan Univ Chin Med，2024，44（4）：565-571.
  67. 67.
    TANG B，LI Q G，LI F，et al.Effect and mechanism of resveratrol on DCS maturation on restoring Th17 / Treg balance in COPD mice based on regulating NF - κB signaling pathway［J］.Chin J Gerontol，2023，43（22）：5569-5572.
  68. 68.
    YIN Z L，XIA X T，HU Y B，et al.Effects of wogonin on regulating phosphatidyl inositol 3 kinase/serine threonine protein kinase/nuclear factor κB signaling pathway on helper T cell 17/regulatory T cell balance in rats with chronic obstructive pulmonary disease［J］.Anhui Med Pharm J，2024，28（8）：1523-1528.
  69. 69.
    MA R F，SU M，LI J T，et al.Qizhi Zhoufei granule alleviate chronic obstructive pulmonary disease by regulating Th1/Th2 immunologic balance through notch signaling pathway［J］.Tradit Chin Med Materia Med-World Sci Technol，2024，26（1）：179-189.
  70. 70.
    YU F C，LIU X G，FANG F，et al.Experimental study of Liuwei Buqi recipe on the balance of Th1/Th2 cells in COPD model rats［J］.Shaanxi J Tradit Chin Med，2022，43（2）：161-165.
  71. 71.
    GAO L Y，LUO D，WANG W J.Quercetin alleviates lung aging in COPD mice through the p53-p21-Rb pathway［J］.Med J West China，2024，36（2）：217-221，227.
  72. 72.
    XIE G Y，LIU X G，FANG F，et al.Effects of Liuwei Buqi decoction on lung senescence-associated secretory phenotype and NF-κB/SIRT-1 signaling pathway in rats with COPD［J］.Mod J Integr Tradit Chin West Med，2023，32（16）：2209-2215.
  73. 73.
    HUANG H P，PEI K，QIU X，et al.Effect of Ginkgo biloba extract on ferroptosis in lung tissue of rats with COPD based on glutathione peroxidase 4 signaling pathway［J］.Pract J Cardaic Cereb Pneum Vasc Dis，2024，32（7）：64-70.
  74. 74.
    WU L N，ZHAO M，XU G L.Effect of Qingjin Huatan decoction on COPD of rat inflammatory response by regulating autophagy［J］.Chin J Exp Tradit Med Form，2019，25（18）：30-35.
  75. 75.
    LIU S M，QIANG Z，WU S L，et al.Establishment and metabolomics analysis of a rat model of chronic obstructive pulmonary disease with phlegm-dampness syndrome［J］.Chin J Lab Anim Sci，2023，31（1）：51-63.
  76. 76.
    WANG M Y.［J］.Effective constituents and mechanism study of Shengxian decoction in the treatment of chronic obstructive pulmonary disease based on network pharmacology and metabolomics［D］.Changchun：Jilin University，2023.
  77. 77.
    ZOU J Y，WANG T J，ZANG N Z，et al.Pathogenesis of chronic obstructive pulmonary disease and modulating effect of traditional Chinese medicine：A review［J］.Chin J Exp Tradit Med Form，2025，31（1）：287-298.
  78. 78.
    CUI Y W，ZANG N Z，LI P，et al.Research progress on evaluation methods of macroscopical indicators of disease and syndrome combined with animal models［J］.Chin J Tradit Chin Med Pharm，2024，42（6）：195-198.

Lesen Sie die ganze Passage

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website